TargetBeta
IL18
interleukin 18 · also IGIF, IL1F4, IL-1g, IL-18 · Interleukins
6 programs in company-led studies act on IL18, from 4 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| arumakimig | Novartis | phase 2 | 73 running | IL1B | the company's pipeline |
| aletekitugrule | GlaxoSmithKline | phase 2 | 92 running | – | ChEMBL |
| camoteskimabrule | Apollo Therapeutics | phase 2 | 51 running | – | NCIt |
| GHZ339 | Novartis | phase 2 | 11 running | IL13 | the company's pipeline |
| BLN-481rule | Beeline Medicines | phase 1 | 11 running | – | the studies' text |
| GSK4528287 | GlaxoSmithKline | phase 1 | 11 running | IL23A | the company's pipeline |
Conditions their studies are in
- Dermatitis, Atopic, 3 programs
- Colitis, Ulcerative, 2 programs
- Arthritis, 1 program
- Arthritis, Juvenile, 1 program
- Coronary Disease, 1 program
- Delayed Graft Function, 1 program
- Diabetes Mellitus, 1 program
- Enterocolitis, 1 program
- Hidradenitis Suppurativa, 1 program
- Inflammatory Bowel Diseases, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Apr 22, 2027arumakimig · Novartis · phase 2 · NCT07203001
- Oct 31, 2027camoteskimab · Apollo Therapeutics · phase 2 · NCT07599813
- Nov 24, 2027BLN-481 · Beeline Medicines · phase 1 · NCT07903064
- Mar 5, 2028aletekitug · GlaxoSmithKline · phase 2 · NCT07747480
- Nov 27, 2028GHZ339 · Novartis · phase 2 · NCT06947993
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.